A Phase 2 interventional study of Temozolomide in Carcinoma, Non-Small-Cell Lung, Adenocarcinoma and Carcinoma, Large Cell, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. Temozolomide · Carcinoma, Non-Small-Cell Lung.
Among the 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 2 that started in 2008, is one of 12 in phase 2, and was the 13th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 3
First in 1997; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 16 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc: 14 open now, 26 under way, 18 of them phase 3. Of 65 finished, 49 (75%) have results posted.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 68th largest by enrollment of the 88 interventional ones that give a count, is one of 5 that started in 2008, is one of 24 in phase 2, and was the 14th registered.
Merck & Co., Inc’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 91 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to investigate whether administration of maintenance temozolomide following standard treatment could possibly prevent or delay the onset of brain metastases in patients with controlled non-small cell lung cancer (NSCLC).
This is a Phase 2, open-label, randomized, multicenter study of maintenance temozolomide versus observation in subjects with stable or responding stage III/IV NSCLC to be conducted in conformance with Good Clinical Practices. Subjects will be randomly assigned to a study drug (temozolomide) or observation arm. The study drug will be administered at a dose of 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first. Subjects completing 6 cycles of treatment will be followed up for incidence of brain metastasis for up to 2 years, or until progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed NSCLC.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive temozolomide at a dose of 75 mg/m\^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
Drug: Temozolomide
Observation
5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
Also known as: Temodar®, SCH 52365
Number of Participants Who Had Brain Metastases
Brain Metastases were defined as radiological evidence of brain metastases on magnetic resonance imaging (MRI).
Time frame: Up to 12 months (as measured from day 1 of cycle 1 of standard first-line systemic chemotherapy)
Time to Radiological Central Nervous System (CNS) Progression
Defined as CNS progression as measured by MRI. Time to CNS progression was analyzed using the Kaplan-Meier method.
Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to radiological progression or the last known CNS progression-free date
Time to Progression
The time to progression (per response evaluation criteria in solid tumors \[RECIST\]) was analyzed using the Kaplan-Meier method. Definitions of response per RECIST: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): A decrease of at least 30% in the sum of the longest diameter of target lesions. Progressive Disease (PD): An increase of at least 20% in the sum of the longest diameter of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.
Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to progression or up to 6 cycles (168 days) of study treatment
Overall Survival
The overall survival was analyzed using the Kaplan-Meier method.
Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up
Number of Participants With Brain Metastases at First Progression
Brain Metastases were defined as radiological evidence of brain metastases on MRI.
Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)
Cancer-related Quality of Life (QoL) as Assessed by The European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire C30 Version 3.0 (QLQ-C30), and the EORTC Lung Cancer Module (QLQ-LC13)
The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Scores range from 0 -100. For functional and global QoL scales, higher scores mean a better level of function. For symptom-oriented scales, a higher score means more severe symptoms and a decrease in QoL. The EORTC QLQ-LC13 is a 13-item questionnaire developed to supplement the EORTC QLQ-C30 in lung cancer patients. It has a score range 0-100 with higher scores representing an increase in symptoms.
Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)
Tolerability of Maintenance Temozolomide
Tolerability was defined as number of participants with any adverse event leading to study discontinuation and/or study drug discontinuation.
Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)
| Milestone | Temozolomide Treatment | Observation |
|---|---|---|
| Started | 26 | 27 |
| Completed | 25 | 27 |
| Not completed | 1 | 0 |
| Withdrew: Did not start study treatment | 1 | 0 |
Brain Metastases were defined as radiological evidence of brain metastases on magnetic resonance imaging (MRI).
| participants | Temozolomide Treatment | Observation |
|---|---|---|
| Number of Participants Who Had Brain Metastases | 4 | 3 |
Defined as CNS progression as measured by MRI. Time to CNS progression was analyzed using the Kaplan-Meier method.
| months | Temozolomide Treatment | Observation |
|---|---|---|
| Time to Radiological Central Nervous System (CNS) Progression | NA (14.26 to NA) | NA (NA to NA) |
The time to progression (per response evaluation criteria in solid tumors \[RECIST\]) was analyzed using the Kaplan-Meier method. Definitions of response per RECIST: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): A decrease of at least 30% in the sum of the longest diameter of target lesions. Progressive Disease (PD): An increase of at least 20% in the sum of the longest diameter of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.
| months | Temozolomide Treatment | Observation |
|---|---|---|
| Time to Progression | 11.70 (9.03 to 15.80) | 10.68 (8.54 to 12.68) |
The overall survival was analyzed using the Kaplan-Meier method.
| months | Temozolomide Treatment | Observation |
|---|---|---|
| Overall Survival | 27.14 (13.90 to NA) | 22.54 (14.52 to NA) |
Brain Metastases were defined as radiological evidence of brain metastases on MRI.
No measurements were reported for this outcome.
The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Scores range from 0 -100. For functional and global QoL scales, higher scores mean a better level of function. For symptom-oriented scales, a higher score means more severe symptoms and a decrease in QoL. The EORTC QLQ-LC13 is a 13-item questionnaire developed to supplement the EORTC QLQ-C30 in lung cancer patients. It has a score range 0-100 with higher scores representing an increase in symptoms.
No measurements were reported for this outcome.
Tolerability was defined as number of participants with any adverse event leading to study discontinuation and/or study drug discontinuation.
| participants | Temozolomide Treatment | Observation |
|---|---|---|
| Tolerability of Maintenance Temozolomide | 5 | NA |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Temozolomide Treatment | — | 8/26 (30.8%) | 25/26 (96.2%) |
| Observation | — | 4/27 (14.8%) | 24/27 (88.9%) |
| Event | Temozolomide Treatment | Observation |
|---|---|---|
| DISEASE PROGRESSIONGeneral disorders | 0/26 | 2/27 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 1/26 | 2/27 |
| LYMPHOPENIABlood and lymphatic system disorders | 1/26 | 0/27 |
| PYREXIAGeneral disorders | 1/26 | 0/27 |
| PNEUMONIAInfections and infestations | 1/26 | 0/27 |
| DEHYDRATIONMetabolism and nutrition disorders | 1/26 | 0/27 |
| HYPONATRAEMIAMetabolism and nutrition disorders | 1/26 | 0/27 |
| BACK PAINMusculoskeletal and connective tissue disorders | 1/26 | 0/27 |
| COGNITIVE DISORDERNervous system disorders | 1/26 | 0/27 |
| DYSARTHRIANervous system disorders | 1/26 | 0/27 |
| Event | Temozolomide Treatment | Observation |
|---|---|---|
| FATIGUEGeneral disorders | 15/26 | 4/27 |
| NAUSEAGastrointestinal disorders | 13/26 | 5/27 |
| COUGHRespiratory, thoracic and mediastinal disorders | 7/26 | 7/27 |
| VOMITINGGastrointestinal disorders | 6/26 | 2/27 |
| BACK PAINMusculoskeletal and connective tissue disorders | 6/26 | 4/27 |
| DIARRHOEAGastrointestinal disorders | 5/26 | 4/27 |
| DECREASED APPETITEMetabolism and nutrition disorders | 5/26 | 4/27 |
| DIZZINESSNervous system disorders | 5/26 | 1/27 |
| DEPRESSIONPsychiatric disorders | 1/26 | 5/27 |
| LYMPHOPENIABlood and lymphatic system disorders | 4/26 | 0/27 |
| Age, Continuous(years) | Temozolomide Treatment | Observation | Total |
|---|---|---|---|
| Mean | 64.8 ± 9.4 | 65.1 ± 10.8 | 65.0 ± 10.0 |
| Sex: Female, Male(Participants) | Temozolomide Treatment | Observation | Total |
|---|---|---|---|
| Female | 12 | 11 | 23 |
| Male | 14 | 16 | 30 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Mar 2008 to primary completion in Jan 2011, 34 months.
Results were first posted in Mar 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Temozolomide
Carcinoma, Non-Small-Cell Lung →